LOUIS MATIS, M.D.
Medical Practice at Flintlock Rd, Southport, CT

6355245, Mar 12, 2002

Jun 7, 1995

08/487283

Mark J. Evans - Cheshire CT
Louis A. Matis - Southport CT
Eileen Elliott Mueller - East Haven CT
Steven H. Nye - Mequon WI
Scott Rollins - Monroe CT
Russell P. Rother - Cheshire CT
Jeremy P. Springhorn - Cheshire CT
Stephen P. Squinto - Bethany CT
Thomas C. Thomas - Madison CT
James A. Wilkins - Woodbridge CT

Alexion Pharmaceuticals, Inc. - Cheshire CT

A61K 39395

4241451, 4241301, 4241331, 4241351, 4241411, 4241581, 4241391, 424130, 5303871, 5303873, 5303879, 5303881, 53038823, 53038825, 5303887, 435326, 435328, 435331, 435 33 L, 435337, 435343, 435346

The use of anti-C5 antibodies, e. g. , monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

7384915, Jun 10, 2008

Jun 3, 2005

11/143947

Yi Wang - Orange CT, US
John Mueller - Old Lyme CT, US
Louis A. Matis - Southport CT, US

Alexion Pharmaceuticals, Inc. - Cheshire CT

C07K 14/62, C07K 14/435, A61K 38/17, A61K 38/28, A61K 38/43

514 3, 514866, 530303, 530350, 530403, 536234

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.

2006005, Mar 9, 2006

Jun 3, 2005

11/143943

Yi Wang - Orange CT, US
John Mueller - Old Lyme CT, US
Louis Matis - Southport CT, US

Alexion Pharmaceuticals, Inc. - Cheshire CT

C07K 14/62, C12N 15/09

530303000, 435069400, 435320100, 435325000

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.

6982323, Jan 3, 2006

Mar 21, 2000

09/528225

Yi Wang - Orange CT, US
John Mueller - Old Lyme CT, US
Louis A. Matis - Southport CT, US

Alexion Pharmaceuticals, Inc. - Cheshire CT

C07K 14/62, C07K 14/435, A61K 38/17, A61K 38/28, A61K 38/43

530403, 530303, 530350, 536 234, 514 3, 514866

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.

7405279, Jul 29, 2008

Jun 3, 2005

11/143966

Yi Wang - Orange CT, US
John Mueller - Old Lyme CT, US
Louis A. Matis - Southport CT, US

Alexion Pharmaceuticals, Inc. - Cheshire CT

C07K 14/62, C07K 14/435, A61K 38/17, A61K 38/28, A61K 38/43

530403, 530303, 530350, 536 234, 514 3, 514866

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.

7279158, Oct 9, 2007

Jan 5, 2005

11/029017

Yi Wang - Orange CT, US
Louis Matis - Southport CT, US

Alexion Pharmaceuticals, Inc. - Cheshire CT

A61K 39/395, C07K 16/00, C12Q 1/00, G01N 33/53

4241301, 4241411, 4241451, 4241521, 4241581, 4241721, 424810, 514825, 514885, 53038825, 5303893, 530868, 435 4, 435 71, 435 72, 435 724, 435 29, 436821

The use of compounds that block complement component C5 or its active fragments C5and/or C5(such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.

2003017, Sep 18, 2003

Jun 2, 1997

08/867612

YI WANG - ORANGE CT, US
LOUIS MATIS - SOUTHPORT CT, US

A01N025/00, A01N043/26, A01N043/12, A61K031/335, A61K031/34, C12P021/08, C07K016/00, C07D313/16, C07D313/06, A61K039/395, C07D307/94, C07D311/96

424/141100, 424/145100, 424/158100, 514/462000, 549/345000, 514/825000, 530/388250, 530/389300

The use of compounds that block complement component or its active fragments Cand/or C(such compounds collectively referred to as “Cblockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such Cblockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.

6074642, Jun 13, 2000

May 2, 1994

8/236208

Yi Wang - Orange CT
Louis Matis - Southport CT
Scott Rollins - Monroe CT

Alexion Pharmaceuticals, Inc. - New Haven CT

A61K 39395

4241451

The use of anti-C5 antibodies, e. g. , monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN.

5891645, Apr 6, 1999

Jun 1, 1994

8/252493

Scott Rollins - Monroe CT
Russell P. Rother - Cheshire CT
Louis A. Matis - Southport CT
Mark J. Evans - Cheshire CT

Alexion Pharmaceuticals, Inc. - New Haven CT

C12N 1512, C12N 1563, C12N 1585, C12P 2102

435 691

A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.